Ortega CMJ, Cornelio RG, Rodríguez WF, Díaz GE

Language: Spanish
References: 22
Page: 127-132
PDF size: 176.78 Kb.

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) has become the most frequent cause of chronic liver disease worldwide, is considered the hepatic manifestation of metabolic syndrome. Most epidemiologic studies derive from non-invasive techniques, such as the ultrasound. Objective: To evaluate the presence of NAFLD by ultrasound and its association with biochemical alterations with metabolic syndrome, without taking into consideration anthropometric measures. Material and methods: Observational, transversal and retrospective study. It was performed in asymptomatic and apparently healthy Mexican population that had a check up performed at the Diagnostic Clinic at Hospital Ángeles Pedregal, Mexico City in the time frame between 1st of May to the 31st of August 2018 with a total of 513 cases. Results: Prevalence of NAFLD found by ultrasound was 28.65% (147 cases). It was shown that serum glucose, triglyceride, HDL and VLDL cholesterol levels, aspartate and alanine aminotransferase had statistically significant p; the association with the male gender and the increase in age were also associated with HGNA. Conclusion: The presence of NAFLD by ultrasound, even incidentally, should compel clinicians to start a complete metabolic diagnosis.

REFERENCES

1. Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med. 2018; 33 (1): 64-74.

2. Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I et al. The Mexican consensus on nonalcoholic fatty liver disease. Rev Gastroenterol Mex. 2019; 84 (1): 69-99.

3. Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol. 2010; 194 (3): 623-628.

4. López-Velázquez JA, Silva-Vidal KV, Ponciano-Rodríguez G, Chávez-Tapia NC, Arrese M, Uribe M et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol. 2014; 13 (2): 166-178.

5. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic teatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001; 121: 91-100.

6. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl Med. 2010; 363 (4): 1341-1350.

7. Wang RT, Koretz RL, Yee HF Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003; 115: 554-559.

8. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990; 12: 1106-1110.

9. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34: 274-285.

10. Lizardi-Cervera J, Becerra LI, Chávez-Tapia NC et al. Prevalencia de hígado graso no alcohólico y síndrome metabólico en población asintomática. Rev Gastroenterol Mex. 2006; 71 (4): 453-459.

11. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 2004; 89: 2563-2568.

12. Csendes GP, Paolinelli GP, Busel MD, Venturelli AV, Rodríguez J. Hígado graso: ultrasonido y correlación anatomopatológica. Rev Chil Radiol. 2004; 10 (2): 50-52.

13. Kramer H, Pickhardt PJ, Kliewer MA, Hernando D, Chen GH, Zagzebski JA et al. Accuracy of liver fat quantification with advanced CT, MRI, and ultrasound techniques: prospective comparison with MR spectroscopy. AJR Am J Roentgenol. 2017; 208 (1): 92-100.

14. Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014; 20: 7392-7402.

15. Reeder SB, Cruite I, Hamilton G et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011; 34 (4): 729-749.

16. Allison DB, Heshka S. Toward an empirically derived typology of obese persons. Int J Obes. 1991; 15: 741-754.

17. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005; 366: 1640-1649.

18. Yu SJ, Kim W, Kim D, Yoon JH, Lee K, Kim JH et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2015; 94 (48): e2159.

19. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis. 2007; 17: 129-139.

20. Rumack C, Wilson S, Charboneau W. Diagnostic ultrasound. 2a. edición. St. Louis, MO: Mosby; 1998. pp. 110-112.

21. Maximos M, Brill F, Portillo Sanchez P et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015; 61 (1): 153-160.

22. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 745-750.